LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,423,412
تعداد دریافت فایل اصل مقاله11,296,547
Afshar, Saeid, Sedighi Pashaki, Abdolazim, Najafi, Rezvan, Nikzad, Safoora, Amini, Razieh, Shabab, Nooshin, Khiabanchian, Omid, Tanzadehpanah, Hamid, Saidijam, Massoud. (1398). Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib. سامانه مدیریت نشریات علمی, 45(1), 50-58. doi: 10.30476/ijms.2019.44972
Saeid Afshar; Abdolazim Sedighi Pashaki; Rezvan Najafi; Safoora Nikzad; Razieh Amini; Nooshin Shabab; Omid Khiabanchian; Hamid Tanzadehpanah; Massoud Saidijam. "Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib". سامانه مدیریت نشریات علمی, 45, 1, 1398, 50-58. doi: 10.30476/ijms.2019.44972
Afshar, Saeid, Sedighi Pashaki, Abdolazim, Najafi, Rezvan, Nikzad, Safoora, Amini, Razieh, Shabab, Nooshin, Khiabanchian, Omid, Tanzadehpanah, Hamid, Saidijam, Massoud. (1398). 'Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib', سامانه مدیریت نشریات علمی, 45(1), pp. 50-58. doi: 10.30476/ijms.2019.44972
Afshar, Saeid, Sedighi Pashaki, Abdolazim, Najafi, Rezvan, Nikzad, Safoora, Amini, Razieh, Shabab, Nooshin, Khiabanchian, Omid, Tanzadehpanah, Hamid, Saidijam, Massoud. Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib. سامانه مدیریت نشریات علمی, 1398; 45(1): 50-58. doi: 10.30476/ijms.2019.44972

Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib

Iranian Journal of Medical Sciences
مقاله 7، دوره 45، شماره 1، فروردین 2020، صفحه 50-58    اصل مقاله (701.12 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2019.44972
نویسندگان
Saeid Afshar1؛ Abdolazim Sedighi Pashaki2؛ Rezvan Najafi1؛ Safoora Nikzad3؛ Razieh Amini1؛ Nooshin Shabab1؛ Omid Khiabanchian4؛ Hamid Tanzadehpanah1؛ Massoud Saidijam* 1
1Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2Mahdieh Radiotherapy and Brachytherapy Charitable Center, Hamadan, Iran
3Department of Medical Physics, Hamadan University of Medical Sciences, Hamadan, Iran
4Medical Laboratory, Besat Hospital, Hamadan, Iran
چکیده
Background: Usually, chemoradiotherapy can be used for the treatment of locally advanced colorectal cancer (CRC) before surgery. On the other hand, some studies have shown that fractional radiation of tumor cells leads to chemoresistance. The aim of this study was to evaluate the chemoresistance of radioresistant sub-line (RR sub-line).
Methods: This study was done in Hamadan University of Medical Sciences in 2017-2018. MTT assay and sub-G1 fraction analysis by flow cytometry were used to evaluate cross-resistance of RR sub-line to gefitinib and regorafenib. Real-time PCR was used to investigate the role of four miRNAs and their target genes in the cross-resistance of RR sub-line. The t test and repeated measures test were used for the assessment of statistical significance between groups.
Results: The IC50 of gefitinib and regorafenib for RR sub-line were significantly higher than those of the parental cell line. On the other hand, the resistance index of RR sub-line for gefitinib and regorafenib were 1.92 and 1.44, respectively. The sub-G1 fraction of RR sub-line following treatment with gefitinib and regorafenib was significantly lower than that of the parental cell line (P=0.012 and P=0.038, respectively). The expression of miR-9, Let-7e, and Let-7b in RRsub-line was significantly lower than that of the parental cell line. However, NRAS, IGF1R, NFKB1, and CCND1 found to be upregulated in RR sub-line in comparison with the parental cell line.
Conclusion: We can conclude that the acquired RR sub-line was cross-resistance to gefitinib and regorafenib. Furthermore, miR-9/NFKB1, let-7b/CCND1, let-7e/NRAS, and IGF1R played essential roles in the chemoradioresistance of CRC.
کلیدواژه‌ها
Colorectal neoplasms؛ Drug Resistance؛ MicroRNAs؛ Gefitinib؛ Regorafenib
سایر فایل های مرتبط با مقاله
مراجع
  1. Geng L, Wang J. Molecular effectors of radiation resistance in colorectal cancer. Precis Radiat Oncol. 2017;1:27-33. doi: 10.1002/pro6.5.
  2. Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014;89:300-13. doi: 10.1016/j.critrevonc.2013.08.003. PubMed PMID: 24041630.
  3. Carr BI, Cavallini A, Lippolis C, D’Alessandro R, Messa C, Refolo MG, et al. Fluoro-Sorafenib (regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol. 2013;228:292-7. doi: 10.1002/jcp.24148. PubMed PMID: 22777740; PubMed Central PMCID: PMCPMC4509637.
  4. Majithia N, Grothey A. regorafenib in the treatment of colorectal cancer. Expert Opin Pharmacother. 2016;17:137-45. doi: 10.1517/14656566.2016.1118054. PubMed PMID: 26559195.
  5. Yar Saglam AS, Alp E, Elmazoglu Z, Menevse S. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines. Hum Exp Toxicol. 2016;35:526-43. doi: 10.1177/0960327115595686. PubMed PMID: 26183715.
  6. Williamson JS, Jones HG, Williams N, Griffiths AP, Jenkins G, Beynon J, et al. Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype. World J Gastrointest Oncol. 2017;9:209-17. doi: 10.4251/wjgo.v9.i5.209. PubMed PMID: 28567185; PubMed Central PMCID: PMCPMC5434388.
  7. Moulder JE, Hopwood LE, Volk DM, Davies BM. Radiation induction of drug resistance in RIF-1: correlation of tumor and cell culture results. Int J Radiat Oncol Biol Phys. 1991;20:213-6. PubMed PMID: 1991681.
  8. Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8:59950-64. doi: 10.18632/oncotarget.19048. PubMed PMID: 28938696; PubMed Central PMCID: PMCPMC5601792.
  9. Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat. 2011;14:280-96. doi: 10.1016/j.drup.2011.08.001. PubMed PMID: 21955833.
  10. Singh PK, Campbell MJ. The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. Cancers (Basel). 2013;5:998-1019. doi: 10.3390/cancers5030998. PubMed PMID: 24202331; PubMed Central PMCID: PMCPMC3795376.
  11. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010;46:298-311. doi: 10.1016/j.ejca.2009.10.027. PubMed PMID: 19948396.
  12. Yang XD, Xu XH, Zhang SY, Wu Y, Xing CG, Ru G, et al. Role of miR-100 in the radioresistance of colorectal cancer cells. Am J Cancer Res. 2015;5:545-59. PubMed PMID: 25973296; PubMed Central PMCID: PMCPMC4396051.
  13. He J, Hua J, Ding N, Xu S, Sun R, Zhou G, et al. Modulation of microRNAs by ionizing radiation in human gastric cancer. Oncol Rep. 2014;32:787-93. doi: 10.3892/or.2014.3246. PubMed PMID: 24919435.
  14. Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology. 2013;145:1133-43. doi: 10.1053/j.gastro.2013.07.048. PubMed PMID: 23916944.
  15. Ahmed FE, Vos PW, Jeffries C, Wiley JE, Weidner DA, Mota H, et al. Differences in mRNA and microRNA microarray expression profiles in human colon adenocarcinoma HT-29 cells treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). Cancer Genomics Proteomics. 2009;6:109-27. PubMed PMID: 19451095.
  16. Khoshinani HM, Afshar S, Pashaki AS, Mahdavinezhad A, Nikzad S, Najafi R, et al. Involvement of miR-155/FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line. Jpn J Radiol. 2017;35:664-72. doi: 10.1007/s11604-017-0679-y. PubMed PMID: 28879560.
  17. Lombardo T, Anaya L, Kornblihtt L, Blanco G. Median effect dose and combination index analysis of cytotoxic drugs using flow cytometry. Flow Cytometry-Recent Perspectives. London: IntechOpen; 2012.
  18. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1:1458-61. doi: 10.1038/nprot.2006.238. PubMed PMID: 17406435.
  19. Pozarowski P, Darzynkiewicz Z. Analysis of cell cycle by flow cytometry. Methods Mol Biol. 2004;281:301-11. doi: 10.1385/1-59259-811-0:301. PubMed PMID: 15220539.
  20. Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int J Cancer. 2008;123:2939-49. doi: 10.1002/ijc.23902. PubMed PMID: 18803287.
  21. Witkos TM, Koscianska E, Krzyzosiak WJ. Practical Aspects of microRNA Target Prediction. Curr Mol Med. 2011;11:93-109. PubMed PMID: 21342132; PubMed Central PMCID: PMCPMC3182075.
  22. Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol. 2006;208:220-8. doi: 10.1002/jcp.20659. PubMed PMID: 16575905.
  23. Mutlu P, Baran Y, Ural AU, Avcu F, Dirican B, Beyzadeoglu M, et al. Effect of cobalt-60 (gamma radiation) on multidrug-resistant multiple myeloma cell lines. Cell Biol Int. 2011;35:721-5. doi: 10.1042/CBI20100061. PubMed PMID: 21241250.
  24. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets. 2009;13:339-62. doi: 10.1517/14712590902735795. PubMed PMID: 19236156; PubMed Central PMCID: PMCPMC2670612.
  25. Xiao M, Cai J, Cai L, Jia J, Xie L, Zhu Y, et al. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J Ovarian Res. 2017;10:24. doi: 10.1186/s13048-017-0321-8. PubMed PMID: 28376831; PubMed Central PMCID: PMCPMC5379542.
  26. Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol. 2010;52:698-704. doi: 10.1016/j.jhep.2009.12.024. PubMed PMID: 20347499.
  27. Stahlhut C, Slack FJ. Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle. 2015;14:2171-80. doi: 10.1080/15384101.2014.1003008. PubMed PMID: 25714397; PubMed Central PMCID: PMCPMC4615025.
  28. Kothari V, Mulherkar R. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma. Anticancer Res. 2012;32:121-8. PubMed PMID: 22213296.
  29. Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and their downstream targets. Biochim Biophys Acta. 2007;1773:1177-95. doi: 10.1016/j.bbamcr.2007.01.012. PubMed PMID: 17428555.
  30. Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, et al. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res. 2014;164:411-23. doi: 10.1016/j.trsl.2014.06.005. PubMed PMID: 25016932.
  31. Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res. 2015;75:2489-500. doi: 10.1158/0008-5472.CAN-14-3167. PubMed PMID: 25870145; PubMed Central PMCID: PMCPMC4605607.
  32. Fang W, Fan Y, Fa Z, Xu J, Yu H, Li P, et al. microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma. Oncotarget. 2017;8:13253-63. doi: 10.18632/oncotarget.14710. PubMed PMID: 28129648; PubMed Central PMCID: PMCPMC5355093.
  33. Salendo J, Spitzner M, Kramer F, Zhang X, Jo P, Wolff HA, et al. Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g. Radiother Oncol. 2013;108:451-7. doi: 10.1016/j.radonc.2013.06.032. PubMed PMID: 23932154.
  34. Shali H, Ahmadi M, Kafil HS, Dorosti A, Yousefi M. IGF1R and c-met as therapeutic targets for colorectal cancer. Biomed Pharmacother. 2016;82:528-36. doi: 10.1016/j.biopha.2016.05.034. PubMed PMID: 27470393.
  35. Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, et al. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. Clin Cancer Res. 2016;22:1767-76. doi: 10.1158/1078-0432.CCR-15-1677. PubMed PMID: 26561558; PubMed Central PMCID: PMCPMC4818693.
  36. Park YR, Lee ST, Kim SL, Liu YC, Lee MR, Shin JH, et al. MicroRNA-9 suppresses cell migration and invasion through downregulation of TM4SF1 in colorectal cancer. Int J Oncol. 2016;48:2135-43. doi: 10.3892/ijo.2016.3430. PubMed PMID: 26983891.
  37. Li Y, Zhao L, Li N, Miao Y, Zhou H, Jia L. miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. Oncol Rep. 2017;37:2193-200. doi: 10.3892/or.2017.5464. PubMed PMID: 28260112.
  38. Courtois G, Gilmore TD. Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene. 2006;25:6831-43. doi: 10.1038/sj.onc.1209939. PubMed PMID: 17072331.
  39. Andersen V, Vogel U, Godiksen S, Frenzel FB, Saebo M, Hamfjord J, et al. Low ABCB1 gene expression is an early event in colorectal carcinogenesis. PLoS One. 2013;8:e72119. doi: 10.1371/journal.pone.0072119. PubMed PMID: 23977225; PubMed Central PMCID: PMCPMC3747088.
آمار
تعداد مشاهده مقاله: 5,200
تعداد دریافت فایل اصل مقاله: 2,786


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب